Ergotamine tartrate + Caffeine Suppositories Rx
Generic Name and Formulations:
Ergotamine tartrate 2mg, caffeine 100mg; rectal supp.
Various generic manufacturers
Indications for Ergotamine tartrate + Caffeine Suppositories:
Migraine, migraine variants, cluster headaches.
1 supp rectally at onset of attack, then 1 supp after 1 hour if needed; max 2 supps/attack, 5 supps/week.
Peripheral vascular disease. Coronary heart disease. Hypertension. Hepatic or renal dysfunction. Sepsis. Concomitant potent CYP3A4 inhibitors (eg, ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) or other vasoconstrictors. Labor & delivery. Pregnancy (Cat.X).
Monitor for ergotism; do not exceed recommended dose. Nursing mothers: not recommended.
See Contraindications. Potentiated by CYP3A4 inhibitors (eg, protease inhibitors, macrolides, azole antifungals, saquinavir, nefazodone, fluoxetine, fluvoxamine, grapefruit juice, zileuton), propranolol, nicotine. Severe hypertension with sympathomimetics.
Vasoconstrictive complications or ergotism (eg, ischemia, cold extremities, vasospasm, ECG changes, hyper- or hypotension, numbness, gangrene, dizziness), precordial or muscle pain, tachycardia, bradycardia, nausea, vomiting, local edema, itching; rarely: retroperitoneal and pleuropulmonary fibrosis, cardiac valve fibrosis (chronic use).
Supps formerly known under the brand names Cafergot, Migergot.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies